Spyre Therapeutics公布了一项临床试验的更新数据,显示有二十名受试者出现了治疗引发的不良事件。其中,两例被评估为严重级别,但经过分析,这些严重事件均被判定与试验药物本身无关。
Spyre Therapeutics公布了一项临床试验的更新数据,显示有二十名受试者出现了治疗引发的不良事件。其中,两例被评估为严重级别,但经过分析,这些严重事件均被判定与试验药物本身无关。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.